Precursor T-Cell Lymphoblastic Leukemia-Lymphoma clinical trials

The registry lists 420 studies for Precursor T-Cell Lymphoblastic Leukemia-Lymphoma across more than 10 countries. 76 are recruiting or about to start. 101 of them are mainly about Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.

Get an email when these change. Save the Precursor T-Cell Lymphoblastic Leukemia-Lymphoma studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 209
Recruiting: 60
Terminated: 58
Status unknown: 32
Withdrawn: 24
Active, not recruiting: 17

Phase

Phase 1: 214
Phase 2: 161
Phase 3: 32
Early Phase 1: 9
Phase 4: 2

Where

United States: 285
China: 51
Italy: 27
Germany: 23
France: 23
Canada: 15

Who runs them

National Cancer Institute (NCI) (58) · Fred Hutchinson Cancer Center (19) · Memorial Sloan Kettering Cancer Center (13) · City of Hope Medical Center (11) · M.D. Anderson Cancer Center (11) · Mayo Clinic (10) · National Institutes of Health Clinical Center (CC) (9) · Case Comprehensive Cancer Center (8)

What is being tested here

Drugs under test in Precursor T-Cell Lymphoblastic Leukemia-Lymphoma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Venetoclax	11	1	17
Cyclophosphamide	5	2	25
Dexamethasone	5	0	7
Daratumumab	5	1	5
Azacitidine	4	0	8
Cytarabine	4	1	7
Fludarabine	3	1	26
Nelarabine	3	2	12
Bortezomib	3	2	10
Dasatinib	3	1	7

Drug classes tested here Antimetabolites 14 open · Alkylating agents 7 open · Corticosteroids 5 open · Tyrosine kinase inhibitors (TKIs) 5 open · Proteasome inhibitors 3 open

Coming up

9phase 3 studies under way

21studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Jan 2027PD-1 Inhibitors +Venetoclax+CAG Regimens in R/R T-ALL · Phase 3 · Fujian Medical University Union Hospital
Nov 2026Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma · Yale University
Nov 2026CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia · National University Hospital, Singapore
Dec 2026Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients · The First Affiliated Hospital of Soochow University
Dec 2026A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex) · Allotera Therapeutics
Dec 2026Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting · M.D. Anderson Cancer Center
Dec 2026Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL · Peking University People's Hospital
Dec 2026A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies · Beijing GoBroad Hospital
Mar 2027Novel Therapeutic Approach for Human T-cell Malignancies · Istituto Oncologico Veneto IRCCS
Mar 2027Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies · Beijing Biotech

Who these studies take

Of the 60 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 24 (40%) set no upper age limit and 31 (52%) stop at 75 or younger. 36 (60%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (2%) take healthy volunteers.

Recruiting studies that take each age, of 60
Age	Women	Men
10	30 (50%)	30 (50%)
18	58 (97%)	58 (97%)
30	48 (80%)	48 (80%)
40	45 (75%)	45 (75%)
50	44 (73%)	44 (73%)
65	43 (72%)	43 (72%)
75	35 (58%)	35 (58%)
85	29 (48%)	29 (48%)

Across all 420 studies, recruiting or not: 34% stop at 75 or younger and 19% at 65; 38% take children; 0% are for women only and 0% for men only; 1% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Precursor T-Cell Lymphoblastic Leukemia-Lymphoma studies take

Of 44 phase 2 interventional studies under Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 63 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 1	56 mo39–76 · 42 studies	—	—
Phase 2	63 mo39–97 · 44 studies	—	64 mo43–97 · 41 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 14, 2026.

Results posted1

SPARK-ALL: Calaspargase Pegol in Adults With ALLOct 29, 2026NCT04817761

Studies

Recruiting first, then most recently updated. Showing 50 of 420. Browse all 420 → or search them.